Chris Packard, Professor of Vascular Biochemistry at the University of Glasgow, UK, looks forward to fresh insights into the contrasting results of the REDUCE-IT and PROMINENT trials and the impact of changes in triglyceride-rich lipoproteins on atherosclerosis.